C-reactive protein, fibrinogen, lipoprotein (a), and lipid profile levels and platelet counts in ischemic stroke patients

Neurosciences

Volumn 12, Issue 3, 2007, Pages 202-206

  Sadreddini, Seyyed A ^a,c   Abolfathi, Ali A ^a   Khandagi, Reza ^a   Talebi, Mahnaz ^a   Lakian, Attusa ^b  

^a UNIVERSITY OF TABRIZ   (Iran)

^b Neurology Polyclinic   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOCYTE COUNT;

EID: 34548552589     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Kagan A, Harres BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, et al. Epidemiologic studies of coronary heart diseases and stroke in Japanese men living in Japan, Hawaii and California: Demographic, physical, dietary and biochemical characteristics. J Chron Dis 1974; 27: 345-364.
2. [No authors listed] The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO Monica project principal investigators. J Clin Epidemiol 1988; 41: 105-114.
3. Harmsen P, Rosengrem A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Gothenburg, Sweden. Stroke 1990; 21: 223-229.
4. Kagan A, Poffer JS, Rhoads GG, Yanko K. Dietary and other risk factors for stroke in Hawaiian Japanese men. Stroke 1985; 16: 390-396.
5. Kannel WB, Gordon T, Dawber TR. Role of lipids in the development of brain infraction: the Framingham study. Stroke 1974; 5: 679-685.
6. Rizor E, Mikhailidis DP. Are high-density lipoprotein (HDL) and triglycerides levels relevant in stroke preventions Cardiovas Res 2001; 52: 199-207.
7. Chein KL, Sung FC, Hsu HC, Su TC, Line RS, Lee YT. Apolipoprotein A-I and B and stroke events in a community-based cohort in Taiwan: report of the Chin-Shan Community Cardiovascular Study. Stroke 2002; 33: 39-45.
8. Mclean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen GY, Fless GM, et al. CDNA sequence of human apoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-137.
9. Jovicic A, Ivaniservic V, Ivanovic I. Lipoprotein (a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993; 98: 59-65.
10. Ario AA, Tach C, Tracy R. LP (a) lipoprotein, vascular disease and mortality in the elderly. N Engl J Med 2003; 349: 2108-2115.
11. Iwamoto T, Feng Y, Shinozaki K, Kayama S, Oyama T, Takazaki M. Clinical significance of lipoprotein (a) in carotid plaque types and ischemic stroke in the elderly. Geriatrics and Gerontology International 2003; 3: 93-100.
12. Colas JL, Montalescot G, Tribouilloy C. Fibrinogen: a cardiovascular risk factor. Presse Med 2000; 34: 1862-1866.
13. Kroger K, Buss C, Goyen M, Renzing-Kohler K, Rudofsky G. Risk factors in young patients with peripheral atherosclerosis. Int Angiol 2000; 19: 206-211.
14. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, et al. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 2001; 111: 457-463.
15. Ridker, PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other Markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
16. Ridker PM. High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
17. Dinapali M, Papar F, Bocola V. C-reactive protein in Ischemic stroke an independent prognostic factor. Stroke 2001; 32: 917-924.
18. Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001; 4: CD001342.
19. Junghans U, Seitz RJ, Aulich A, Freund HJ, Siebler M. Bleeding risk of tirofiban, a nonpeptide GPTLbIIIIa platelets receptor antagonist in progressive stroke: an open pilot stroke study. Cerebrovasc Dis 2001; 12: 308-312.
20. Ralph LS. Pathogenesis, classification, and epidemiology of cerebrovascular disease. In: Rowland LP, editor. Merritt's Neurology. 11th ed. Philadelphia (PA): Williams & Wilkins; 2005. p. 275-290.
21. Kroger K, Buss C, Goyen M, Renzing-Kohler K, Rudofsky G. Risk factors in young patients with peripheral atherosclerosis. Int Angiol 2000; 19: 206-211.
22. Velcheva I, Antonova N, Dimitrova V, Dimitrov N, Ivanov I. Plasma lipids and blood viscosity in patients with cerebrovascular disease. Clin Hemorheol Microcirc 2006; 35: 155-157.
23. Scherle CE, Nasiff A, Begueria RA, Perez-Nellar J, Colina-Rodriguez AJ. Lipids and lipoproteins in a group of patients with ischemic cerebrovascular disease. Rev Neurol 1998; 27: 804-808.
24. Hamsen P, Rosengreen A, Tsipogianni A, Withelmsen L. Risk factor for stroke in middle-aged men in Gotenborg, Sweden. Stroke 1990; 21: 223-229.
25. Kagan A, Popper JS, Rhoade GG, Yano K. Dietary and other risk factors for stroke in Hawaian Japanese men. Stroke 1985; 16: 390-396.
26. Zivkovic SA, Lopez OL, Zaretsky M, Wechsler LR. Rapidly progressive stroke in a young adult with very low high-density lipoprotein in cholesterol. J Neuroimaging 2000; 10: 233-236.
27. Laloux P, Galanti L, Jamart J. Lipids in ischemic stroke subtype. Acta Neurol Belg 2004; 104: 13-19.
28. Chien KL, Sung FC, Hsu HC, Su TC, Lin RS, Lee YT. Apolipoprotein A-I and B and stroke events in a community Based cohort in Taiwan. Stroke 2002; 33: 39-44.
29. Arnilas JF, Chacon P, Montner J, Sanchez E, Alvareg-Sabin J. High lipoprotein (a), diabetes and the extent of symptomatic intracranial atherosclerosis. Neurology 2004; 63: 27-32.
30. Van kooten F, Van krimpen J, Dippel DW, Hoogerbrugge N, Koudrtaal PJ. Lipoprotein (a) in patients with acute cerebral ischemia. Stroke 1996; 72: 1231-1235.
31. Ridker PM, Stamfer MJ, Heinekens CH. Plasma concentration of lipoprotein (a) and the risk of future stroke. JAMA 1995; 273: 1269-1273.
32. Neguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abulebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-1394.
33. Morrisett JD. The role of lipoprotein (a) in atherosclerosis. Curr Atheroscler Rep 2000; 2: 243-250.
34. Honczarenko K, Torbus-Lisiecka B, Osuch Z, Nocon D, Nowacki P, Potemkowski A, et al. [Fibrinogen and lipids: associated risk factors for ischemic cerebral stroke]. Neurol Neurochir Pol 1999; 33: 557-565.
35. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-126.
36. Elkind MS, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RR. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol 2006; 166: 37.
37. Ford ES, Giles WH. Serum C-Reactive protein and self-reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20: 1052-1056.
38. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reative protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000; 20: 1047-1051.
39. Di Napoli M, Papa F, Bacola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001; 32: 133-138.
40. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol 2000; 23 Suppl 6: VI-18-22.
41. Zhu CY, Cui LY, Hua BL, Pan JQ. Correlation between fibrinogen level and cerebral infarction. Clin Med Sci J 2006; 21: 167-170.
42. Qizilbash N. Fibrinogen and cerebrovascular disease. Eur Heart J 1995; 16 Suppl A: 42-45; discussion 45-46.
43. D'Erasmo E, Acca M, Celi FS, Medici F, Palmerini T, Pisani D. Plasma fibrinogen and platelet count in stroke. J Med 1993; 24: 1851-1891.
44. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, et al. Prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 2001; 111: 457-463.
45. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57 (5 Suppl 2): S5-S7.
46. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol 2000; 23 Suppl 6: VI-18-22.
47. Rupin A, Martin F, Vallez MO, Bonhomme E, Verbeuren TJ. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb Haemost 2001; 86: 1528-1531.
48. Sacco RL. Reducing the risk of stroke in diabetes, what have we learned that is new? Diabetes Obes Metab 2002; 4 Suppl 1: S27-S34.
49. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, Bordet R. Stroke prevention, management of modifiable vascular risk factors. J Neurol 2002; 249: 507-517.
50. Mouradian MS, Majumdar SR, Senthilselven A, Khan K, Shuaib A. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke 2002; 33: 1656-1659.
51. Ansari AK, Akhundi A, Shaikh AQ. Stroke in elderly; identification of risk factors. J Ayub Med Coll Abbottabad 2001; 3: 11-13.
52. Tohgi H, Konno S, Takahashi S, Koizumi D, Kondo R, Takahasli H. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb Res 2000; 100: 373-379.